Abstracts tagged "Biomarkers"

Abstract Number: 1417 • 2018 ACR/ARHP Annual Meeting
Hemophagocytic Lymphohistiocytosis (HLH) Mimickers: CXCL9 As a Potential Biomarker Distinguishing HLH from Other Hyperferritinemic Syndromes
Giulia Marucci¹, Ivan Caiello², Manuela Pardeo¹, Virginia Messia¹, Giusi Prencipe¹, Antonia Pascarella¹, Fabrizio De Benedetti³ and Claudia Bracaglia¹, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Increased ferritin is considered biomarker highly suggestive of primary and secondary HLH and it is one of the HLH-2004 diagnostic and MAS guidelines (1,2),…
Abstract Number: 1907 • 2018 ACR/ARHP Annual Meeting
High Serum Adiponectin Associates with the Incidence of Rheumatoid Arthritis in Obese Subjects
Cristina Maglio¹, Yuan Zhang², Christian Herder³, Anna Rudin⁴ and Lena Carlsson⁵, ¹Dep. of Rheumatology and Inflammation Research and Wallenberg Centre for Molecular and Translational Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dep. of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³German Diabetes Center, Düsseldorf, Germany, ⁴Dept of Rheumatology and Inflammation Research, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Adiponectin, a cytokine mainly produced by the adipose tissue, plays an important role in several metabolic and inflammatory processes. In obese subjects, serum adiponectin…
Abstract Number: 2682 • 2018 ACR/ARHP Annual Meeting
Novel Antibody Against Commensal Bacterial Antigen in Prediction of the Response of Rituximab in Systemic Lupus Erythematosus
Yu-Min Kuo^1,2, Jenhao Chen³, Jean-san Chia⁴, Chiau-jing Jung⁵ and Song-Chou Hsieh⁶, ¹Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, Taipei, Taiwan, ²Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ³Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital,Yunlin branch, Yunlin County, Taiwan, ⁴Graduate Institute of Immunology, National Taiwan University College of Medicine, Taipei, Taiwan, ⁵Department of Microbiology and Immunology, School of Medicine,, College of Medicine, Taipei Medical University, Taipei, Taiwan, ⁶National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Streptoccocal infections can cause rheumatic fever sharing clinical presentations similar to SLE. Whether oral commensal streptococci could induce cross-reactive and pathogenic antibodies remained unknown.…
Abstract Number: 577 • 2018 ACR/ARHP Annual Meeting
Expanded Autoantibody Profiles Predict Treatment Response to Biologic Therapy in Rheumatoid Arthritis
Ted R. Mikuls¹, Amrita Bath², Bryant R. England³, Michael J. Duryee⁴, Carlos D. Hunter⁴, Joel Kremer⁵, Dimitrios A. Pappas^6,7, William H. Robinson⁸, Jeffrey R. Curtis⁹ and Geoffrey M. Thiele¹⁰, ¹Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵Albany Medical Center, Albany, NY, ⁶Columbia University, New York, NY, ⁷Corrona, LLC, Waltham, MA, ⁸Stanford University, Palo Alto, CA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Although biologics represent a major advance in rheumatoid arthritis (RA), many patients fail to achieve adequate responses to these agents. As previous studies have…
Abstract Number: 989 • 2018 ACR/ARHP Annual Meeting
Reduction of Serum IL17F and IL22 By IL23p19 Blockade with Guselkumab Is Associated with Improvement in Joint Symptoms in Psoriatic Arthritis
Qingxuan Song, Matthew Loza, Karen Leander, Brittney Scott, Patrick Branigan and Kristen Sweet, Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Guselkumab (GUS) is a fully human monoclonal antibody that binds to the p19 subunit of IL23. In a recent Phase 2 study, GUS demonstrated…
Abstract Number: 1426 • 2018 ACR/ARHP Annual Meeting
The Utilization of S100 Proteins Testing in Pediatric Rheumatology Patients in a Tertiary Care Institution and Implications for Care
Najla Aljaberi¹, Angela Merritt², Alexei Grom¹, Grant Schulert³, Jennifer L. Huggins⁴, Michael Henrickson⁵ and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children’s Medical Center, Cincinnati, OH
Background/Purpose: S100 proteins are calcium-binding proteins of increasing value as biomarkers in various inflammatory conditions (e.g. autoinflammatory diseases, vasculitides, inflammatory bowel disease). The two highly…
Abstract Number: 1973 • 2018 ACR/ARHP Annual Meeting
Leveraging Publicly Available Gene Expression Data and Applying Machine Learning to Identify Novel Biomarkers for Rheumatoid Arthritis
Dmitry Rychkov¹, Marina Sirota² and Cindy Lin³, ¹Institute for Computational Health Sciences, University of Calfornia, San Francisco, San Francisco, CA, ²Pediatrics, Institute for Computational Health Sciences, University of California, San Francisco, San Francisco, CA, ³Stanford, Stanford, CA
Background/Purpose: Diagnosis and monitoring the disease progression of RA is challenging requiring a combination of imaging techniques and blood tests. There is currently no biochemical…
Abstract Number: 2690 • 2018 ACR/ARHP Annual Meeting
Potential Markers of Skin Involvement in Systemic Sclerosis
Radim Becvar¹, Hana Storkanova², Barbora Sumova¹, Maja Spiritovic¹, Sabina Oreska², Ladislav Šenolt¹ and Michal Tomcik², ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Skin fibrosis is a hallmark of systemic sclerosis (SSc). There are no widely accepted biomarkers of skin involvement in this condition. Several serum or…
Abstract Number: 583 • 2018 ACR/ARHP Annual Meeting
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
Cristina Ruiz-Romero¹, Florencia Picchi², Lucia González², Rebecca Hands³, Valentina Calamia², Patricia Fernández⁴, Maria Camacho², Rocío Paz², Conrad Bessant⁵, Costantino Pitzalis³ and Francisco J Blanco⁶, ¹Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁴Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁵School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, ⁶Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a…
Abstract Number: 1042 • 2018 ACR/ARHP Annual Meeting
Development of a Neo-Epitope Specific Assay for Serological Assessment of Type X Collagen Degradation and Its Potential Diagnostic Value for Knee Osteoarthritis
Yi He¹, Tina Manon-Jensen², Lars Arendt-Nielsen^3,4, Kristian Petersen³, Thorbjørn Gantzel⁵, Jonathan Samuels⁶, Steven B. Abramson⁷, Morten A. Karsdal⁸, Mukundan Attur⁹ and Anne C. Bay-Jensen⁸, ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Department of Health Science and Technology, Aalborg University, Aalborg, Denmark, ⁴C4Pain, Aalborg, Denmark, ⁵cOrthopedic Surgery Unit, Gentofte Hospital, Hellerup, Denmark, ⁶Department of Medicine, Divison of Rheumatology, NYU Langone Health, New York, NY, ⁷Dept of Medicine, NYU Langone Health, New York, NY, ⁸Nordic Bioscience, Herlev, Denmark, ⁹Rheumatology Research, NYU Langone Orthopedic Hospital, New York, NY
Background/Purpose: Phenotypic changes of chondrocytes toward hypertrophy might be fundamental in the pathogenesis of OA, of which type X collagen is a well-known marker. The…
Abstract Number: 1442 • 2018 ACR/ARHP Annual Meeting
Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolome Profile with Consistent Accuracy for Rheumatoid Arthritis
Walter P. Maksymowych¹, Xiaohang Wang², Joel Paschke¹, Rana Dadashova¹, Edna Hutchings¹ and Liang Li², ¹CaRE Arthritis, Edmonton, AB, Canada, ²Chemistry, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is hampered by suboptimal accuracy of currently available serological biomarkers. Recent advancements in metabolomic profiling include dansylation liquid…
Abstract Number: 1983 • 2018 ACR/ARHP Annual Meeting
Mutations Associated with Clonal Hematopoiesis of Indeterminate Potential Are Found in Peripheral Blood and Synovial Fluid Macrophages from Patients with Rheumatoid and Psoriatic Arthritis
Maria De Santis¹, Matteo Zampini², Natasa Isailovic¹, Elena Generali¹, Giacomo Maria Guidelli¹, Matteo Della Porta² and Carlo Selmi^1,3, ¹Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ²Oncology and Hematology Unit, Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy
Background/Purpose: Myeloidmutations commonly associated to neoplasia in patients who do not meet the diagnostic criteria for myelodysplastic syndrome are coined as clonal hematopoiesis of indeterminate…
Abstract Number: 2775 • 2018 ACR/ARHP Annual Meeting
Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica
Claire Owen^1,2, Christopher McMaster², David Liew^1,2, Jessica Leung^1,2, Andrew Scott^3,4,5 and Russell Buchanan^2,6, ¹Medicine, University of Melbourne, Parkville VIC, Australia, ²Rheumatology, Austin Health, Heidelberg VIC, Australia, ³Medicine, University of Melbourne, Heidelberg VIC, Australia, ⁴Molecular Imaging and Therapy, Austin Health, Heidelberg VIC, Australia, ⁵Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg VIC, Australia, ⁶Medicine, University of Melbourne, Parkville, Australia
Background/Purpose: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been demonstrated to correlate with disease activity and predict treatment response in…
Abstract Number: 584 • 2018 ACR/ARHP Annual Meeting
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Borja Hernández-Breijo^1,2, Israel Gañán-Nieto³, Cristina Sobrino³, Victoria Navarro-Compán¹, Ana Martínez^1,2, Carlota García-Hoz³, Javier Bachiller³, María Gema Bonilla Hernán^1,4, Garbiñe Roy⁵, Mónica Vázquez³, Alejandro Balsa^1,6, Luisa María Villar³, Dora Pascual-Salcedo¹, Eulalia Rodríguez-Martín³ and Chamaida Plasencia^1,4, ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²Immunology. La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology. Ramón y Cajal University Hospital and IRYCIS, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFi) are widely used for the treatment of rheumatoid arthritis (RA). This study aims to analyse the profile of peripheral blood mononuclear…
Abstract Number: 1049 • 2018 ACR/ARHP Annual Meeting
Optical Biomarkers for the Early Diagnosis of Osteoarthritis
Paula Casal Beiroa^1,2, Elena F. Burguera^2,3,4, Tamara Hermida-Gómez^2,3,4, Noa Goyanes⁵, Natividad Oreiro^4,6, Pío González⁷, Francisco J Blanco⁸ and Joana Magalhaes^2,4,9, ¹Unidad de Medicina Regenerativa. Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC). CHUAC. SERGAS., A Coruña, Spain, ²Centro de Investigaciones Científicas Avanzadas (CICA), Universidad de A Coruña (UDC)., a coruña, Spain, ³Unidad de Medicina Regenerativa, Grupo de Investigación en Reumatología, Agrupación Estratégica CICA-INIBIC, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade de A Coruña (UDC), A Coruña, Spain, ⁴Centro de Investigación Biomédica en Red (CIBER), madrid, Spain, ⁵Centro de Investigaciones Científicas Avanzadas (CICA), Universidad de A Coruña (UDC)., A Coruña, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña. España, A Coruna, Spain, ⁷Grupo de Nuevos Materiales. Departamento de Física Aplicada. Universidad de Vigo., Vigo, Spain, ⁸Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade de A Coruña (UDC), A Coruña, Spain, ⁹Unidad de Medicina Regenerativa. Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC). CHUAC. SERGAS., a coruña, Spain
Background/Purpose: Osteoarthritis (OA) is a rheumatic disease characterized by articular cartilage degradation. On its early stages, OA is asymptomatic and its current gold-standard diagnosis (X-Rays),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].